- Citations, last 5 years
- 15
- Works, last 5 years
- 10
- h-index
- 20
- Scientists listed
- 0
- Grants since 2016
- 1
Grants received
2016–2018 · contract · N44
IGF::OT::IGF: SBIR PHASE II, TOPIC 326: DEVELOPMENT OF NOVEL THERAPEUTIC AGENTS THAT TARGET CANCER STEM CELLS
David Eavarone · Siamab Therapeutics (United States) · funded by National Institutes of Health
